Novartis AG Receives Positive Results For Ofatumumab In Phase III Multiple Sclerosis Studies

  • Aug 30, 2019 BST
  • Team Kalkine

Novartis AG (LSE:0QLR) has received positive results for ofatumumab (OMB157) from the Phase III ASCLEPIOS I and II studies evaluating the safety and efficacy of ofatumumab 20mg monthly subcutaneous injections over Aubagio®14mg daily oral tablets. Ofatumumab demonstrated superiority over Aubagio® (teriflunomide) in patients with relapsing forms of multiple sclerosis (RMS), in both head-to-head studies.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK